6GPS
CRYSTAL STRUCTURE OF CCR2A IN COMPLEX WITH MK-0812
Summary for 6GPS
Entry DOI | 10.2210/pdb6gps/pdb |
Related | 5t1a |
Descriptor | C-C chemokine receptor type 2,Rubredoxin,C-C chemokine receptor type 2, ZINC ION, [(3~{S},4~{S})-3-methoxyoxan-4-yl]-[(1~{R},3~{S})-3-propan-2-yl-3-[[3-(trifluoromethyl)-7,8-dihydro-5~{H}-1,6-naphthyridin-6-yl]carbonyl]cyclopentyl]azanium (3 entities in total) |
Functional Keywords | gpcr, signalling, drug-design, signaling protein |
Biological source | Homo sapiens (Human) More |
Total number of polymer chains | 1 |
Total formula weight | 48814.14 |
Authors | Pautsch, A.,Schnapp, G. (deposition date: 2018-06-07, release date: 2019-01-02, Last modification date: 2019-03-13) |
Primary citation | Apel, A.K.,Cheng, R.K.Y.,Tautermann, C.S.,Brauchle, M.,Huang, C.Y.,Pautsch, A.,Hennig, M.,Nar, H.,Schnapp, G. Crystal Structure of CC Chemokine Receptor 2A in Complex with an Orthosteric Antagonist Provides Insights for the Design of Selective Antagonists. Structure, 27:427-438.e5, 2019 Cited by PubMed Abstract: We determined two crystal structures of the chemokine receptor CCR2A in complex with the orthosteric antagonist MK-0812. Full-length CCR2A, stabilized by rubredoxin and a series of five mutations were resolved at 3.3 Å. An N- and C-terminally truncated CCR2A construct was crystallized in an alternate crystal form, which yielded a 2.7 Å resolution structure using serial synchrotron crystallography. Our structures provide a clear structural explanation for the observed key role of residue E291 in high-affinity binding of several orthosteric CCR2 antagonists. By combining all the structural information collected, we generated models of co-structures for the structurally diverse pyrimidine amide class of CCR2 antagonists. Even though the representative Ex15 overlays well with MK-0812, it also interacts with the non-conserved H121, resulting in a significant selectivity over CCR5. Insights derived from this work will facilitate drug discovery efforts directed toward highly selective CCR2 antagonists with potentially superior efficacy. PubMed: 30581043DOI: 10.1016/j.str.2018.10.027 PDB entries with the same primary citation |
Experimental method | X-RAY DIFFRACTION (3.3 Å) |
Structure validation
Download full validation report